TS-068425 — Functionalization of scFvs with cyclic peptide linkers

TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment

TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…

TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…

TS-066750 — The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…

TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.

TS-065913 — Gene therapy strategies for treating peripheral neuropathy.

TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …

TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.

TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health

TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…

TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.

TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…

TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…